Date: Jun 17, 2013 Source: bizjournals (
click here to go to the source)
A Towson biotechnology firm is moving into a new office and laboratory at the University of Maryland BioPark in Baltimore after receiving a National Institutes of Health grant to expand its research.
Ocular Proteomics LLC, which is working on a technology to more accurately diagnose retinal diseases, will have about 3,000 square feet of space for conducting new research on macular degeneration and for working with more clinical trial patients, said Dr. Bert Glaser, the company's chief science officer. The company recently won a $1.2 million Small Business Innovation in Research (SBIR) phase 2 grant from NIH and the extra space to expand the scope of its research.
The move will allow the company to collaborate with University of Maryland scientists and tap into the biopark's resources.
"It's a wonderful move for us," Glaser said.
Ocular is a spin off of the National Retina Institute, which Glaser founded in 1989.
Ocular previously had a small lab in Towson.
At its new space, the company plans to work with about 200 patients for its clinical trials.
